GGrantIndex
Sort

15,440 grants matching organoids

Sex steroid signaling and adaptive growth of the intestine

$472,704
Bruce A Edgar · University Of Utah · R01 · FY2023 · DK

Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer

$472,698
Tony R. Hunter · Salk Institute For Biological Studies · P01 · FY2024 · CA

Coordinated regulation of alternative pre-mRNA processing in colon cancer

$472,634
Klemens J Hertel · University Of California-Irvine · R01 · FY2015 · CA

Induction and Evolution of Metaplasia in the Stomach

$472,614
James R Goldenring · Vanderbilt University Medical Center · R01 · FY2020 · DK

DEVELOPMENTAL FUNDS (Core-002)

$472,600
Beverly Shriver Mitchell · Stanford University · P30 · FY2019 · CA

Epigenetic dysregulation in APC-negative colorectal cancer

$472,530
Nathan A. Ellis · University Of Arizona · R01 · FY2023 · CA

Functional consequences of mutations in spliceosomal small nuclear RNAs

$472,491
Richard A Padgett · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · GM

Preclinical and clinical characterization of DNMT inhibitors +/- standard chemoimmunotherapy in TNBC

$472,447
Liewei Wang · Mayo Clinic Rochester · R01 · FY2025 · CA

3-Dimensional Retinal Organoid Platform for the Study of Retinoblastoma

$472,438
Daniel Pelaez · University Of Miami School Of Medicine · R01 · FY2022 · CA

3D Bioprinted Spinal Cord Organoids as a Relay System for Spinal Cord Injury

$472,298
Ann M Parr · University Of Minnesota · R01 · FY2024 · NS

Core 3: Mouse Models Core (MM Core)

$472,258
Geoffrey Myles Wahl · Salk Institute For Biological Studies · P01 · FY2024 · CA

Novel Approaches for Improving Inflammation Resolution Following Chronic Exposure to Air Pollutants

$472,252
Srinivasa Reddy · University Of California Los Angeles · R01 · FY2023 · ES

The Evolution of Sarcoma Drug Sensitivity through Time and Space

$472,053
Alice Soragni · University Of California Los Angeles · R01 · FY2024 · CA

Variant-to-gene mapping for brain related traits and disorders

$471,924
Alessandra Chesi · University Of Pennsylvania · R35 · FY2023 · HG

An NADH-ChREBP axis in fatty liver disease and dyslipidemia

$471,860
Russell Paul Goodman · Massachusetts General Hospital · R01 · FY2025 · DK

Network modulation to improve gene therapy in CLN3 disease

$471,780
Rebecca Clare Ahrens-Nicklas · Children'S Hosp Of Philadelphia · R56 · FY2022 · NS

Stem Cell-Based Models for Elucidating Human Adrenocortical Development and Dysfunction

$471,752
Kotaro Sasaki · University Of Pennsylvania · R01 · FY2024 · DK

Targeting oncogenic dopamine receptor signaling in glioblastoma

$471,662
Jeongwu Lee · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · CA

Targeting oncogenic dopamine receptor signaling in glioblastoma

$471,662
Jeongwu Lee · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · CA

Project 3: Transcriptomic subtypes, response predictions, and therapy selection

$471,647
Jen Jen Yeh · Univ Of North Carolina Chapel Hill · P50 · FY2022 · CA

Role of the renal organic anion transporter OAT1 in metabolism and physiology

$471,623
Sanjay K Nigam · University Of California, San Diego · R01 · FY2019 · GM

The selective advantage of mismatch repair loss in colonic stem cells

$471,589
Christopher D. Heinen · University Of Connecticut Sch Of Med/Dnt · R01 · FY2022 · CA

Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence

$471,586
Charles L Sawyers · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA

Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence

$471,586
Charles L Sawyers · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA

Role of Intestinal Autophagy in the Pathogenesis of Alcohol Associated Liver Disease

$471,559
Paul Gideon Thomes · Auburn University At Auburn · R01 · FY2025 · AA